The recent publication, "Factors Impacting the Immunogenicity of Etrolizumab & Clinical Consequences," examined key determinants of immunogenicity for etrolizumab.
While Etrolizumab can induce anti-drug antibodies (ADAs) in some individuals, driven by genetic and immunologic factors, these ADAs do not appear to significantly affect treatment efficacy or safety.
Given the minimal clinical impact, the findings support a more refined approach to patient selection and monitoring, with greater emphasis on efficacy drivers and subgroup-specific responses.
Read the full article and learn more about the study's findings at :https://link.springer.com/article/10.1208/s12248-025-01090-1
#Immunogenicity #Etrolizumab #ClinicalPharmacology
------------------------------
Pankajini Mallick Ph.D.
Sr. Principal Scientist, DMPK, PK/PD
San Diego CA
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------